-
MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping
•
China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration with the Human Cell Atlas (HCA) consortium, marking a significant step forward in the human cell mapping initiative. This partnership aims to expand access to MGI’s proprietary products within the HCA network by offering discounted…
-
MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions
•
MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic collaboration with Belgium’s OncoDNA, a company specializing in precision medicine for cancer and genetic diseases. The partnership integrates the OncoDEEP Kit’s comprehensive workflow—including sequencing, secondary analysis, and final interpretation of next-generation sequencing (NGS) data through…
-
MGI Tech Joins Forces with Dasa to Enhance Precision Medicine in Brazil Through Advanced Genomic Sequencing
•
MGI Tech Co., Ltd, a leading gene sequencing company based in China, has announced a strategic collaboration with Dasa, Latin America’s largest medical diagnostics company. This partnership aims to integrate Dasa’s extensive patient service network with MGI’s advanced gene sequencing platform, thereby advancing precision medicine in Brazil. The collaboration will…
-
MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02
•
MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a previous collaboration with the Haihe Laboratory of Cell Ecosystem under the China Academy of Medical Sciences, which commenced under the ‘SEQ ALL’ multi-omics initiative. This partnership initially led to the establishment of a multi-omics DCS…
-
MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into a strategic partnership with fellow Chinese firm Sequanta Technologies Co., Ltd, marking a significant step with the establishment of the “Sequanta-MGI DCS Lab.” The DCS Lab is a state-of-the-art facility equipped with cutting-edge technology, including…
-
MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has announced a strategic collaboration with Predica Diagnostics, a Netherlands-based company. Under this partnership, MGI will provide support to Predica in the development of targeted RNA sequencing tests utilizing MGI’s next-generation sequencing platforms. While the financial details of…
-
Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China
•
Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership with fellow Chinese firm MGI Tech Co., Ltd. (SHA: 688114). This collaboration will result in the creation of Kindstar’s multi-omics DCS Lab service center, which will be focused on serving the Central China region. Kindstar…
-
BioSecure Act Advances in US, Aiming to Curb Ties with Chinese Bioscience Firms
•
US legislators are working expeditiously to finalize the BioSecure Act, legislation that, if enacted, would restrict interactions between US companies and several Chinese life sciences firms. According to details obtained by FiercePharma.com from recent amendments to the draft law, existing contracts between US firms and the listed Chinese entities will…
-
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
•
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity” bill proposal that could have significant implications for the biotechnology industry. The bipartisan-supported bill aims to prohibit companies receiving US government funding from engaging in commercial dealings with certain biotech companies identified as national security…
-
Bristol-Myers Squibb Prepares Contingency Plans in Response to the Biosecure Act
•
Bristol-Myers Squibb (BMS; NYSE: BMY), a leading U.S. pharmaceutical company, is reportedly drafting ‘contingency plans’ to address the potential implications of the Biosecure Act, which is currently under legislative review in the United States. As detailed by the Financial Times, BMS’s CFO, David Elkins, disclosed on a media call that…
-
MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe
•
MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins Genomics Europe Genotyping A/S, headquartered in France. As part of the deal, Eurofins has placed a corporate order for MGI’s DNBSEQ-T20×2 (T20) ultra-high throughput sequencer, which is accompanied by the genomics data center ZTRON Appliance,…
-
MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications
•
China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements with eight companies to develop applications based on the G99 sequencing platform. The financial details of these agreements have not been disclosed. DNBSEQ-G99: A Miniaturized Sequencing PlatformDNBSEQ-G99, launched by MGI Tech, is a miniaturized dual…
